Robocath concludes first European clinical study to demonstrate safety and efficacy of robotic coronary angioplasty performed with R-One
11 January 2022
Study results will be presented at EuroPCR conference in Paris, France, May 2022.
Rouen, France, January 11, 2022 – Robocath, a company that designs, develops and commercializes innovative robotic platforms for the treatment of vascular diseases, announces today that it has concluded its ‘R-Evolution’ clinical study.
The study was aimed at assessing the safety and efficacy of the R-OneTM robotic assistance platform. Sixty-two patients across six European hospital centers participated: the university hospitals in Rouen and Caen with Prof. Durand…
